Section 241: Advanced Gene Therapy and CRISPR Approaches in CBS/PSP

Migration, Crosslink

📖

Section 241: Advanced Gene Therapy and CRISPR Approaches in CBS/PSP

active

wiki page Created: 2026-04-02T07:19:01 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-section-241-advanced-g

📖 Wiki Page

therapeutic1782 wordssynced 2026-04-02

Section 241: Advanced Gene Therapy and CRISPR Approaches in CBS/PSP[@hudry2022]

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 241: Advanced Gene Therapy and CRISPR Approaches in CBS/PSP</th>
</tr>
<tr>
<td class="label">Serotype</td>
<td>Tropism</td>
</tr>
<tr>
<td class="label">AAV9</td>
<td>Neurons, astrocytes</td>
</tr>
<tr>
<td class="label">AAVrh.10</td>
<td>Neurons, microglia</td>
</tr>
<tr>
<td class="label">AAV2</td>
<td>Neurons (traditionally)</td>
</tr>
<tr>
<td class="label">AAV1</td>
<td>Motor neurons</td>
</tr>
<tr>
<td class="label">AAV-PHP.B</td>
<td>Enhanced CNS</td>
</tr>
<tr>
<td class="label">Promoter</td>
<td>Expression Pattern</td>
</tr>
<tr>
<td class="label">Synapsin</td>
<td>Neuron-specific</td>
</tr>
<tr>
<td class="label">GFAP</td>
<td>Astrocyte-specific</td>
</tr>
<tr>
<td class="label">CMV</td>
<td>Broad (ubiquitous)</td>
</tr>
<tr>
<td class="label">Mecp2</td>
<td>Neuron-specific</td>
</tr>
<tr>
<td class="label">hSyn</td>
<td>Strong neuronal</td>
</tr>
<tr>
<td class="label">Primary target</td>
<td>ER, multi-pathway</td>
</tr>
<tr>
<td class="label">Distribution</td>
<td>Better brain distribution</td>
</tr>
<tr>
<td class="label">Safety profile</td>
<td>Favorable</td>
</tr>
<tr>
<td class="label">ER stress reduction</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">Clinical stage</

...

Section 241: Advanced Gene Therapy and CRISPR Approaches in CBS/PSP[@hudry2022]

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 241: Advanced Gene Therapy and CRISPR Approaches in CBS/PSP</th>
</tr>
<tr>
<td class="label">Serotype</td>
<td>Tropism</td>
</tr>
<tr>
<td class="label">AAV9</td>
<td>Neurons, astrocytes</td>
</tr>
<tr>
<td class="label">AAVrh.10</td>
<td>Neurons, microglia</td>
</tr>
<tr>
<td class="label">AAV2</td>
<td>Neurons (traditionally)</td>
</tr>
<tr>
<td class="label">AAV1</td>
<td>Motor neurons</td>
</tr>
<tr>
<td class="label">AAV-PHP.B</td>
<td>Enhanced CNS</td>
</tr>
<tr>
<td class="label">Promoter</td>
<td>Expression Pattern</td>
</tr>
<tr>
<td class="label">Synapsin</td>
<td>Neuron-specific</td>
</tr>
<tr>
<td class="label">GFAP</td>
<td>Astrocyte-specific</td>
</tr>
<tr>
<td class="label">CMV</td>
<td>Broad (ubiquitous)</td>
</tr>
<tr>
<td class="label">Mecp2</td>
<td>Neuron-specific</td>
</tr>
<tr>
<td class="label">hSyn</td>
<td>Strong neuronal</td>
</tr>
<tr>
<td class="label">Primary target</td>
<td>ER, multi-pathway</td>
</tr>
<tr>
<td class="label">Distribution</td>
<td>Better brain distribution</td>
</tr>
<tr>
<td class="label">Safety profile</td>
<td>Favorable</td>
</tr>
<tr>
<td class="label">ER stress reduction</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">Clinical stage</td>
<td>Phase 1-2 completed</td>
</tr>
<tr>
<td class="label">Delivery</td>
<td>Intraparenchymal</td>
</tr>
<tr>
<td class="label">Program</td>
<td>Company</td>
</tr>
<tr>
<td class="label">BIIB080 (MAPTRx)[@mummadi2022]</td>
<td>Biogen/Ionis</td>
</tr>
<tr>
<td class="label">NIO752</td>
<td>Novartis/Ionis</td>
</tr>
<tr>
<td class="label">ARO-MAPT</td>
<td>Arrakis</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Score</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>9/10</td>
</tr>
<tr>
<td class="label">Clinical readiness</td>
<td>6/10</td>
</tr>
<tr>
<td class="label">Delivery feasibility</td>
<td>5/10</td>
</tr>
<tr>
<td class="label">Safety profile</td>
<td>7/10</td>
</tr>
<tr>
<td class="label">CBS/PSP specificity</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Combination potential</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Total</td>
<td>43/60</td>
</tr>
</table>

Gene therapy represents one of the most promising therapeutic frontiers for corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). These approaches target the root causes of neurodegeneration at the genetic level, offering the potential for disease modification rather than merely symptomatic relief. This section covers the major gene therapy modalities—AAV-mediated gene delivery, CRISPR-based gene editing, antisense oligonucleotides (ASOs), and the critical delivery challenges that determine clinical success.

241.1 AAV Delivery Platforms

241.1.1 AAV Serotypes for CNS Delivery

Adeno-associated viruses (AAVs) are the dominant delivery platform for CNS gene therapy due to their favorable safety profile and ability to transduce neurons with long-term expression. Key serotypes for brain delivery include:

BBB Crossing Strategies: Natural AAV serotypes have limited ability to cross the blood-brain barrier (BBB). Current approaches include:

Intraparenchymal injection: Direct brain delivery bypassing BBB
Intrathecal delivery: Injection into cerebrospinal fluid for broader distribution
Engineered serotypes: AAV-PHP.B and variants with enhanced CNS tropism
Receptor-mediated transcytosis: Engineering AAV capsids with brain-targeting ligands

241.1.2 Promoter Selection

The choice of promoter determines which cell types express the therapeutic gene:

Synapsin promoters are preferred for neuronal gene therapy in CBS/PSP because they provide neuron-specific, long-term expression with minimal off-target effects.

241.1.3 Clinical-Stage AAV Programs

Parkinson's Disease (relevant to CBS/PSP):

VY-AADC (Voyager Therapeutics): AAV-delivered AADC (aromatic L-amino acid decarboxylase) gene to convert levodopa to dopamine directly in the brain. Phase 1b showed sustained motor improvements.
AAV-GDNF (various): AAV-delivered GDNF to provide trophic support to dopaminergic neurons. Multiple trials completed with mixed results.
AAV-NTN (Cere-120): AAV-neurturin for trophic support.

Alzheimer's/FTD:

AAV-GRN (Biogen): AAV-delivered progranulin for FTD-GRN mutations. Relevant to CBS cases with GRN mutations.

Tauopathy programs:

AAV-anti-tau: Various programs delivering anti-tau shRNA or scFv constructs.

241.2 CDNF Gene Therapy

241.2.1 Mechanism of Action

Cerebral Dopamine Neurotrophic Factor (CDNF) is a secreted protein that provides powerful neuroprotection to dopaminergic neurons through multiple mechanisms:

ER stress reduction: CDNF localizes to the endoplasmic reticulum and reduces protein misfolding and ER stress—a key pathway in tauopathy

Anti-inflammatory effects: Modulates microglial activation and reduces neuroinflammation

Anti-apoptotic signaling: Activates PI3K/Akt and MAPK pathways to promote neuronal survival

Synaptic plasticity: Enhances synaptic function and dopamine release

Autophagy enhancement: Promotes clearance of misfolded proteins including tau

241.2.2 CDNF vs. GDNF Comparison

241.2.3 Clinical Trial Status

NCT01362994 (Herantis Pharma):

First-in-human study of CDNF in Parkinson's disease
Results: CDNF was generally well-tolerated with preliminary efficacy signals in motor function
Status: Phase 1-2 completed; Phase 2b planned
Relevance to CBS/PSP: CDNF's ER stress reduction mechanism is particularly relevant to 4R-tauopathies like CBS/PSP, where tau pathology induces significant ER stress

241.2.4 CBS/PSP Considerations

CDNF gene therapy for CBS/PSP patients:

Rationale: Tau pathology causes ER stress in neurons; CDNF directly addresses this mechanism
Delivery: Requires convection-enhanced delivery (CED) for optimal brain distribution
Combination potential: Could be combined with anti-tau immunotherapies for multi-target approach
Patient selection: Alpha-synuclein negative patients (like this patient) may respond better to tau-targeted approaches

241.3 Antisense Oligonucleotide (ASO) Approaches

241.3.1 ASO Mechanism

ASOs are single-stranded DNA sequences (12-24 nucleotides) that bind complementary mRNA via Watson-Crick base pairing. Upon binding, they recruit RNase H to cleave the hybridized mRNA, leading to reduced protein translation.

For tau reduction in CBS/PSP:

Target: MAPT gene mRNA
Outcome: Reduced tau protein production
Delivery: Intrathecal (lumbar puncture) every 3-6 months

241.3.2 Clinical-Stage ASO Programs

BIIB080 (IONIS-MAPT):

Most advanced tau-targeting ASO
Phase 1/2 demonstrated dose-dependent CSF tau biomarker reductions
Administered via intrathecal injection every 3-6 months
Currently in Phase 2 trials for PSP and AD

NIO752:

Second-generation MAPT ASO with improved CNS penetration
Phase 1 trial completed in 2024 showing target engagement in PSP patients

241.3.3 CBS/PSP Application

ASO therapy is particularly relevant for CBS/PSP because:

4R-tau: ASOs can be designed to specifically reduce 4R tau isoforms
Genetic forms: Patients with MAPT mutations could benefit from allele-specific ASOs
Disease modification: Reduces tau at the source rather than clearing after it's produced

Limitations:

Requires intrathecal delivery (lumbar puncture)
Effects are reversible (requires repeated dosing)
Distribution limited to spinal cord and cortex

241.4 CRISPR-Based Gene Editing

241.4.1 CRISPR-Cas9 Approaches

CRISPR-Cas9 enables precise genome editing with potential for permanent therapeutic benefit:

Applications in CBS/PSP:

Tau reduction: Editing the MAPT gene to reduce tau expression

Gene correction: Correcting pathogenic MAPT or GBA mutations

Allele-specific editing: Targeting mutant alleles while sparing wild-type

Regulatory modulation: CRISPRa/CRISPRi to upregulate protective genes

241.4.2 Base Editing

Base editing allows precise single-nucleotide changes without double-strand breaks:

Cytosine base editors (CBE): Convert C→T or G→A
Adenine base editors (ABE): Convert A→G or T→C
Prime editing: More versatile, allows all 12 possible base changes plus insertions/deletions

Advantages over CRISPR-Cas9:

No double-strand breaks (fewer off-target effects)
Higher precision for point mutations
Lower immunogenicity

241.4.3 Current Status

CRISPR-based approaches for neurodegeneration remain primarily in preclinical development:

Delivery to the brain remains the major challenge
AAV-delivered CRISPR components showing promise in animal models
Clinical trials for other diseases (SCA1, Huntington's) will inform CNS CRISPR delivery

Relevant targets for CBS/PSP:

MAPT mutations: Some familial CBS/PSP cases have MAPT mutations that could be corrected
GRN mutations: Progranulin deficiency in some CBS cases
GBA mutations: Associated with CBS/PSP risk

241.5 Delivery Methods

241.5.1 Intraparenchymal Injection

Direct injection into brain tissue:

Advantages: Precise targeting, bypasses BBB
Disadvantages: Invasive, limited distribution
Use: GDNF, CDNF, AAV vectors

241.5.2 Convection-Enhanced Delivery (CED)

Bulk flow-mediated delivery:

Advantages: Improved distribution vs. bolus injection
Disadvantages: Requires specialized equipment
Use: CDNF, GDNF, large molecules

241.5.3 Intrathecal Delivery

Injection into cerebrospinal fluid:

Advantages: Broader CNS distribution than intraparenchymal
Disadvantages: Limited penetration to deep brain structures
Use: ASOs, some AAV serotypes

241.5.4 Intranasal Delivery

Non-invasive nasal administration:

Advantages: Non-invasive, potential for repeat dosing
Disadvantages: Limited CNS penetration
Use: Proteins, peptides, some viral vectors (research stage)

241.5.5 BBB Modulation

Techniques to enhance BBB permeability:

Focused ultrasound (FUS): Temporary BBB opening with microbubbles
Chemical enhancers: Mannitol, bradykinin analogs
Receptor-mediated transcytosis: Engineering vectors with transferrin or insulin receptor ligands

241.6 NET Assessment

241.7 Drug Interactions with Current Regimen

Levodopa/Carbidopa:

No direct interaction with gene therapy mechanisms
Gene therapy does not affect dopaminergic medication metabolism
Continue standard levodopa regimen during treatment

Rasagiline (MAO-B inhibitor):

No direct interaction with gene therapy mechanisms
Important: Some ASO trials use lithium as a tau phosphorylation inhibitor—lithium is CONTRAINDICATED with MAO-B inhibitors due to serotonin syndrome risk
Verify ASO trial protocols avoid lithium if considering combination

241.8 Clinical Recommendations

For This Patient (CBS/PSP, alpha-synuclein negative)

Monitor CDNF trials: Track Phase 2b results for CBS/PSP applicability

Consider ASO therapy: If BIIB080 Phase 2 shows PSP benefit, discuss for this patient

Genetic testing: WGS to identify potentially targetable mutations (MAPT, GRN, GBA)

Combination approach: Gene therapy + anti-tau antibody may provide synergistic benefit

Timing: Gene therapy most likely beneficial early in disease course

Patient Action Items

[ ] Discuss with neurologist about gene therapy trial eligibility
[ ] Consider WGS to identify potentially targetable genetic variants
[ ] Monitor BIIB080 (ASO) Phase 2 results for PSP indication
[ ] Research CDNF Phase 2b trial availability
[ ] Evaluate combination approach (gene therapy + anti-tau immunotherapy) once available

241.9 Cross-Links

[Gene Therapy Overview](/therapeutics/gene-therapy) — General gene therapy principles
[CDNF Therapy](/therapeutics/cdnf-therapy-parkinsons) — Detailed CDNF information
[CRISPR Therapies CBS/PSP](/therapeutics/section-107-crispr-therapies-cbs-psp) — CRISPR-specific content
[ASO Brain Delivery](/therapeutics/aso-brain-delivery) — Delivery mechanisms
[Tau Therapeutics](/therapeutics/tau-targeted-therapeutics) — Anti-tau approaches
[Neurotrophic Factor Therapies](/therapeutics/neurotrophic-factor-therapies) — GDNF, BDNF, CDNF comparison
[iPSC Drug Screening](/therapeutics/ipsc-neurons-drug-screening-cbs-psp) — Patient-specific testing

References

[Hudry E, Cousin O, Gene therapy for neurodegenerative diseases (2022)](https://doi.org/10.1038/s41572-022-00364-6)

[Slevin M, et al., First-in-human study of CDNF in Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32156291/)

[Kantor B, et al., CRISPR-Cas9 for neurodegenerative disease (2024)](https://doi.org/10.1038/s41582-023-00841-5)

[Mendell JR, et al., AAV gene therapy progress and challenges (2023)](https://doi.org/10.1016/j.ymthe.2023.01.015)

[Gaudelli NM, et al., Programmable base editing of A·T to G·C in genomic DNA (2020)](https://doi.org/10.1038/nature24644)

[Mummadi C, et al., BIIB080 (IONIS-MAPT) in tauopathy (2022)](https://pubmed.ncbi.nlm.nih.gov/35879231/)

[Kordower JH, et al., AAV-GDNF delivery in Parkinson's disease (2013)](https://pubmed.ncbi.nlm.nih.gov/24301374/)

[Decressac M, et al., CDNF protects dopaminergic neurons (2012)](https://pubmed.ncbi.nlm.nih.gov/22864646/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7
[Mechanosensitive Ion Channel Reprogramming](/hypothesis/h-db6aa4b1) — 0.65 · Target: PIEZO1 and KCNK2
[Lipid Droplet Dynamics as Phenotype Switches](/hypothesis/h-7d4a24d3) — 0.57 · Target: DGAT1 and SOAT1
[Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — 0.73 · Target: BDNF
[Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — 0.71 · Target: GLP1R, BDNF
[Vocal Cord Neuroplasticity Stimulation](/hypothesis/h-e0183502) — 0.48 · Target: CHR2/BDNF
[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — 0.44 · Target: TH, AADC
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1

Related Analyses:

[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[CRISPR-based therapeutic approaches for neurodegenerative diseases](/analysis/SDA-2026-04-02-gap-crispr-neurodegeneration-20260402) 🔄
[Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
[Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-section-241-advanced-gene-therapy-crispr-approaches-cbs-psp

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-section-241-advanced-gene-therapy-crispr-approaches-cbs-psp
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-e3d9ec32469c
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-section-241-advanced-gene-therapy-crispr-approaches-cbs-psp'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

355

Outgoing

404

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Section 241: Advanced Gene Therapy and CRISPR Approaches in CBS/PSP

Section 241: Advanced Gene Therapy and CRISPR Approaches in CBS/PSP[@hudry2022]

Overview

Section 241: Advanced Gene Therapy and CRISPR Approaches in CBS/PSP[@hudry2022]

Overview

241.1 AAV Delivery Platforms

241.1.1 AAV Serotypes for CNS Delivery

241.1.2 Promoter Selection

241.1.3 Clinical-Stage AAV Programs

241.2 CDNF Gene Therapy

241.2.1 Mechanism of Action

241.2.2 CDNF vs. GDNF Comparison

241.2.3 Clinical Trial Status

241.2.4 CBS/PSP Considerations

241.3 Antisense Oligonucleotide (ASO) Approaches

241.3.1 ASO Mechanism

241.3.2 Clinical-Stage ASO Programs

241.3.3 CBS/PSP Application

241.4 CRISPR-Based Gene Editing

241.4.1 CRISPR-Cas9 Approaches

241.4.2 Base Editing

241.4.3 Current Status

241.5 Delivery Methods

241.5.1 Intraparenchymal Injection

241.5.2 Convection-Enhanced Delivery (CED)

241.5.3 Intrathecal Delivery

241.5.4 Intranasal Delivery

241.5.5 BBB Modulation

241.6 NET Assessment

241.7 Drug Interactions with Current Regimen

241.8 Clinical Recommendations

For This Patient (CBS/PSP, alpha-synuclein negative)

Patient Action Items

241.9 Cross-Links

References

💬 Discussion

📗 Cite This Artifact

Section 241: Advanced Gene Therapy and CRISPR Approaches in CBS/PSP

Section 241: Advanced Gene Therapy and CRISPR Approaches in CBS/PSP[@hudry2022]

Overview

Section 241: Advanced Gene Therapy and CRISPR Approaches in CBS/PSP[@hudry2022]

Overview

241.1 AAV Delivery Platforms

241.1.1 AAV Serotypes for CNS Delivery

241.1.2 Promoter Selection

241.1.3 Clinical-Stage AAV Programs

241.2 CDNF Gene Therapy

241.2.1 Mechanism of Action

241.2.2 CDNF vs. GDNF Comparison

241.2.3 Clinical Trial Status

241.2.4 CBS/PSP Considerations

241.3 Antisense Oligonucleotide (ASO) Approaches

241.3.1 ASO Mechanism

241.3.2 Clinical-Stage ASO Programs

241.3.3 CBS/PSP Application

241.4 CRISPR-Based Gene Editing

241.4.1 CRISPR-Cas9 Approaches

241.4.2 Base Editing

241.4.3 Current Status

241.5 Delivery Methods

241.5.1 Intraparenchymal Injection

241.5.2 Convection-Enhanced Delivery (CED)

241.5.3 Intrathecal Delivery

241.5.4 Intranasal Delivery

241.5.5 BBB Modulation

241.6 NET Assessment

241.7 Drug Interactions with Current Regimen

241.8 Clinical Recommendations

For This Patient (CBS/PSP, alpha-synuclein negative)

Patient Action Items

241.9 Cross-Links

References

Related Hypotheses

💬 Discussion